Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint
Written by Emily J. Thompson, Senior Investment Analyst
Source: businesswire
Updated: Dec 17 2023
0mins
Source: businesswire
Trade with 70% Backtested Accuracy
Stop guessing
"Should I Buy ULTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Sign upAbout the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
REX Shares Names Matt Holcomb as Portfolio Manager for REX IncomeMax™ Option Strategy ETF (Ticker: ULTI)
Appointment of Portfolio Manager: REX Shares has appointed Matt Holcomb as Portfolio Manager for the newly launched REX IncomeMax™ Option Strategy ETF (ULTI), which aims to generate weekly income by writing options on volatile U.S. stocks.
Active Management Strategy: Holcomb will manage a targeted portfolio of 15 to 30 volatile equities, dynamically adjusting the strategy to market conditions to transform volatility into consistent income while managing risk.
Educational Initiative: REX is launching an educational platform where Holcomb will engage with investors through a dedicated X account, aiming to demystify options income strategies and promote transparency in investment management.
Investment Risks: The REX IncomeMax™ ETF involves significant risks, including volatility, options strategy risks, and new fund risks, making it suitable primarily for sophisticated investors who understand these complexities.
Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024
Ultimovacs ASA: Mandatory notification of trade by primary insider
Ultimovacs ASA: Mandatory notification of trade by primary insider